VANCOUVER, BC — November 19, 2025 — Leads & Copy — Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) has initiated a pilot project with Kuano Ltd. to expedite the development of its PNKP Inhibitor Technology, also known as A83B4C63.
The collaboration signifies a crucial advancement in Onco’s mission to leverage advanced technologies, specifically computational platforms, to discover cancer treatment mechanisms and accelerate therapeutic innovation.
The initiative will build on Onco’s ongoing efforts to improve the discovery and evaluation of its proprietary PNKP inhibitor platform. The application of advanced molecular modeling and AI-driven compound design has allowed Onco to refine compound architecture, simplify synthesis pathways, and expand the library of optimized analogs centered on the A83B4C63 scaffold. These improvements strengthen the potential for developing more selective and potent inhibitors and speed up the transition of PNKP candidates toward preclinical validation.
Under the framework of the pilot project, Kuano will use its quantum-ready analytics platform in collaboration with Onco-Innovations to explore structural insights into PNKP inhibition. Kuano’s advanced quantum molecular modeling is expected to provide a detailed characterization of how A83B4C63 interacts with PNKP. This includes an examination of binding poses, conformational changes, and the mechanism of inhibition underlying Onco’s PNKP Inhibitor Technology. These findings are expected to guide structure optimization and generate candidates for Onco’s next-generation of therapeutics.
The pilot project will initially focus on Onco’s PNKP-targeting compounds. The integration of Kuano’s quantum-level analytics within Onco’s AI-enabled discovery environment is aimed at creating a robust framework designed to streamline the path from modeling to validation and synthesis.
Vid Stojevic, CEO and Co-Founder of Kuano, said that the collaboration with Onco-Innovations will apply Kuano’s quantum-enabled platform to a challenging oncology target. Stojevic added that by bringing quantum precision to the molecular level, they aim to bring new insights to PNKP inhibition and help accelerate the design of next-generation therapeutics.
The pilot project is expected to run through the fourth quarter of 2025 and is expected to deliver validated platform outputs, structural binding models, and mechanistic hypotheses. The results will inform follow-on initiatives in quantum-ready QSAR modeling, toxicity mapping, and generative compound design across the broader PNKP Inhibitor Technology pipeline.
Thomas O’Shaughnessy, CEO of Onco-Innovations, said the work with Kuano reflects a clear strategic direction for Onco-Innovations to lead in next-generation oncology through the integration of advanced computational and experimental science. He added that the pilot project represents an important step toward realizing the full potential of their PNKP Inhibitor Technology.
Onco-Innovations Limited specializes in oncology research and treatment. The company has an exclusive worldwide license to patented technology that targets solid tumors.
Thomas O’Shaughnessy, Chief Executive Officer, Tel: + 1 888 261 8055, investors@oncoinnovations.com
Source: Onco-Innovations Limited
